ArticleFEMS microbiology letters2025
Inhibitory activity of meso-dimercaptosuccinic acid against IMP metallo-β-lactamase variants in Pseudomonas aeruginosa.
Article in FEMS microbiology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FirstMicrobiology spectrum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The treatment of infections caused by MBL-producing Pseudomonas aeruginosa, including IMP-producers, can be challenging since MBLs confer resistance to most clinically available ß-lactams, leaving few viable options. Thiol-containing compounds, such as meso-dimercaptosuccinic acid (DMSA), have been suggested as inhibitors of MBLs, and particularly have been proposed to exert effective activity against IMP-1 enzymes. In this context, we sought to determine the activity of DMSA, in combination with carbapenems or cephalosporins, against diverse MBL and carbapenemase variants, particularly focussing on IMP variants. In recombinant strains producing either IMP-1, IMP-10, or IMP-13, both with and without a functional OprD, synergy was observed with ceftazidime (CAZ), cefepime (FEP), and meropenem. Negligible changes were observed for other MBLs and no effect was observed in stains producing KPC-2. Testing of the CAZ/DMSA and FEP/DMSA combinations against clinical IMP-producing P. aeruginosa isolates resulted in fractional inhibitory concentration indexes indicating synergy. Enzymatic assays showed a significantly increased inhibitory activity of DMSA against the IMP variants, compared to the other enzymes tested. These findings highlight a possible role of DMSA or DMSA-like compounds to be developed for the treatment of infections caused by IMP-producing P. aeruginosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.